Active p38α causes macrovesicular fatty liver in mice

Area of Science:

• Hepatology
• Molecular Biology
• Genetics

Background:

• Nonalcoholic fatty liver disease (NAFLD) affects one-third of Western populations and can progress to hepatocellular carcinoma (HCC).
• The precise molecular triggers for NAFLD remain unclear, with the prevailing 'multiple hits model' implicating diverse systemic factors.
• Existing models do not fully explain how fatty liver can develop independently of obesity.

Purpose of the Study:

• To investigate if a single genetic modification within the liver can initiate fatty liver disease.
• To determine the role of the MAP kinase p38α in the pathogenesis of NAFLD.
• To explore the potential of targeting p38α for therapeutic intervention in fatty liver disease.

Main Methods:

• Establishment of a transgenic system for temporally controlled, liver-specific activation of an intrinsically active p38α allele.
• Induction of p38α expression in the liver and assessment of phenotypic changes, including liver fat accumulation and body weight.
• Analysis of gene expression changes associated with p38α activation and investigation of symptom reversal upon deactivation.

Main Results:

• Temporal and liver-specific induction of active p38α was sufficient to cause macrovesicular fatty liver in the absence of obesity.
• Active p38α induced the upregulation of genes such as MUC13, CIDEA, PPARγ, ATF3, and c-jun, some of which are linked to human HCC.
• Reversal of p38α mutant expression led to the resolution of fatty liver symptoms, indicating a reversible disease process.

Conclusions:

• The MAP kinase p38α plays a direct, causative role in the development of fatty liver disease.
• Fatty liver can be induced by a single genetic event in the liver, separate from systemic factors like obesity.
• p38α may be considered a proto-inflammatory gene (proto-inflammagene) and a potential therapeutic target for NAFLD and other chronic inflammatory conditions.